Condition: Advanced Refractory Solid Tumors · Advanced Triple Negative Breast Cancers · Metastatic Triple Negative Breast Cancers · Sponsor: National University Hospital, Singapore
This is a single arm, open-label, phase I dose finding study, followed by a phase II expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of 33 patients with refractory solid tumors to determine the RP2D. In the phase II portion, a total of 30 patients with advanced/metastatic TNBC will be enrolled.
This description comes directly from the study's public registry record.
Soo Chin Lee · 6779 5555 · soo_chin_lee@nuhs.edu.sg
Always discuss trial participation with your own doctor first.
| National University Hospital | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05035745